Overcoming immuno-resistance by rescheduling anti-VEGF/cytotoxics/anti-PD-1 combination in lung cancer model

Abstract

Background: Many tumors are refractory to immune checkpoint inhibitors, but their combination with cytotoxics is expected to improve sensitivity. Understanding how and when cytotoxics best re-stimulate tumor immunity could help overcome resistance to immune checkpoint inhibitors.

Methods:In vivo studies were performed in C57BL/6 mice grafted with immune-refractory LL/2 lung cancer model. A longitudinal immunomonitoring study on tumor, spleen, and blood after multiple treatments including Cisplatin, Pemetrexed, and anti-VEGF, either alone or in combination, was performed, spanning a period of up to 21 days, to determine the optimal time window during which immune checkpoint inhibitors should be added. Finally, an efficacy study was conducted comparing the antiproliferative performance of various schedules of anti-VEGF, Pemetrexed-Cisplatin doublet, plus anti-PD-1 (i.e., immunomonitoring-guided scheduling, concurrent dosing or a random sequence), as well as single agent anti-PD1.

Results: Immunomonitoring showed marked differences between treatments, organs, and time points. However, harnessing tumor immunity (i.e., promoting CD8 T cells or increasing the T CD8/Treg ratio) started on D7 and peaked on D14 with the anti-VEGF followed by cytotoxics combination. Therefore, a 14-day delay between anti-VEGF/cytotoxic and anti-PD1 administration was considered the best sequence to test. Efficacy studies then confirmed that this sequence achieved higher antiproliferative efficacy compared to other treatment modalities (i.e., -71% in tumor volume compared to control).

Conclusions: Anti-VEGF and cytotoxic agents show time-dependent immunomodulatory effects, suggesting that sequencing is a critical feature when combining these agents with immune checkpoint inhibitors. An efficacy study confirmed that sequencing treatments further enhance antiproliferative effects in lung cancer models compared to concurrent dosing and partly reverse the resistance to cytotoxics and anti-PD1.

Keywords

Immune checkpoint inhibitors / cisplatin / pemetrexed / anti-VEGF / non-small cell lung cancer / efficacy study / immunomonitoring

References

[1] Thandra KC,Saginala K,Barsouk A.Epidemiology of lung cancer.Contemp Oncol2021;25:45-52 PMCID:PMC8063897

[2] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[3] Zarogoulidis K,Darwiche K.Treatment of non-small cell lung cancer (NSCLC).J Thorac Dis2013;5 Suppl 4:S389-96 PMCID:PMC3791496

[4] NICE guideline. Lung cancer: diagnosis and management. 2019. Available from: https://www.nice.org.uk/guidance/ng122. [Last accessed on 4 Mar 2024]

[5] Herzberg B,Gainor JF.Immune checkpoint inhibitors in non-small cell lung cancer.Oncologist2017;22:81-8 PMCID:PMC5313266

[6] Fitzhugh DJ.History of immunotherapy: the first 100 years.Immunol Allergy Clin North Am2011;31:149-57,vii

[7] Bagchi S,Engleman EG.Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance.Annu Rev Pathol2021;16:223-49

[8] Ciccolini J,André N,Barlesi F.Combinatorial immunotherapy strategies: most gods throw dice, but fate plays chess.Ann Oncol2019;30:1690-1

[9] Imbs DC,Boyer A.Revisiting bevacizumab + cytotoxics scheduling using mathematical modeling: proof of concept study in experimental non-small cell lung carcinoma.CPT Pharmacometrics Syst Pharmacol2018;7:42-50 PMCID:PMC5784740

[10] Barbolosi D,Lacarelle B,André N.Computational oncology - mathematical modelling of drug regimens for precision medicine.Nat Rev Clin Oncol2016;13:242-54

[11] Nars MS.Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy.Int J Cancer2013;132:2471-8

[12] Laheurte C,Calcagno F.Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer.Int J Cancer2020;147:1199-205

[13] Merritt RE,Yamada RE,Korst RJ.Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer.J Thorac Cardiovasc Surg2003;126:1609-17

[14] Miao Q,Zheng X,Wu B.Transformation of a cold to hot tumor and a durable response to immunotherapy in a patient with non-small cell lung cancer after chemoradiotherapy: a case report.Ann Palliat Med2021;10:4982-6

[15] Liu YT.Turning cold tumors into hot tumors by improving T-cell infiltration.Theranostics2021;11:5365-86 PMCID:PMC8039952

[16] Darnell EP,Baruch EN,Reynolds KL.Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls.Curr Oncol Rep2020;22:39

[17] Paijens ST,de Bruyn M.Tumor-infiltrating lymphocytes in the immunotherapy era.Cell Mol Immunol2021;18:842-59 PMCID:PMC8115290

[18] Zhang Y.The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.Cell Mol Immunol2020;17:807-21 PMCID:PMC7395159

[19] Palmeri M,Silk AW.Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.ESMO Open2022;7:100336 PMCID:PMC8717431

[20] Uehara Y,Kitadai R.Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy.Transl Lung Cancer Res2022;11:135-49 PMCID:PMC8902087

[21] Schaer DA,Dempsey JA.The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade.Cell Rep2018;22:2978-94

[22] Messenheimer DJ,Afentoulis ME.Timing of PD-1 blockade is critical to effective combination immunotherapy with Anti-OX40.Clin Cancer Res2017;23:6165-77 PMCID:PMC5641261

[23] Sicard G,Giacometti S,Ciccolini J.Harnessing tumor immunity with cytotoxics: T cells monitoring in mice bearing lung tumors treated with anti-VEGF and pemetrexed-cisplatin doublet.Br J Cancer2023;129:1373-82 PMCID:PMC10628115

[24] van Moorsel CJ, Pinedo HM, Veerman G, Vermorken JB, Postmus PE, Peters GJ. Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice.Eur J Cancer1999;35:808-14

[25] van Moorsel CJ,Smid K.Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours.Eur J Cancer2000;36:2420-9

[26] van der Wilt CL,Smid K.Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.Cancer Res2001;61:3675-81

[27] Vayne-Bossert P,Good P,Rickett K.Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery).Cochrane Database Syst Rev2017;7:CD012002 PMCID:PMC6379017

[28] Goodman RS,Balko JM.Corticosteroids and cancer immunotherapy.Clin Cancer Res2023;29:2580-7 PMCID:PMC10349688

[29] Ciccolini J,André N,Benzekry S.Mechanistic learning for combinatorial strategies with immuno-oncology drugs: can model-informed designs help investigators?.JCO Precis Oncol2020;4:486-91

[30] Ruiz-Ramírez J,Dogra P.A modeling platform for the lymphatic system.J Theor Biol2020;493:110193 PMCID:PMC7297266